11.45

1.33% 0.15

Artiva Biotherapeutics Inc (ARTV)

Overview News Price History Discussions Forecast

Artiva Biotherapeutics Inc stock is traded at $11.45, with a volume of 264.41K. It is up +1.33% in the last 24 hours and up +22.46% over the past month. Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Previous Close:

$11.30

Open:

$11.24

24h Volume:

264.41K

Relative Volume:

0.51

Market Cap:

$559.79M

Revenue:

$251.00K

Net Income/Loss:

$-87.07M

P/E Ratio:

-3.2259

EPS:

-3.5494

Net Cash Flow:

$-80.18M

1W Performance:

+1.60%

1M Performance:

+22.46%

6M Performance:

+186.25%

1Y Performance:

+324.07%

1-Day Range:

$10.80

$11.59

1-Week Range:

$10.80

$12.27

52-Week Range:

$2.22

$14.53

Artiva Biotherapeutics Inc Stock (ARTV) Company Profile

Name

Artiva Biotherapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(858) 267-4467

Address

5505 MOREHOUSE DRIVE, SAN DIEGO

Employee

106

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

ARTV's Discussions on Twitter

Compare ARTV vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARTV Artiva Biotherapeutics Inc	11.45	563.70M	251.00K	-87.07M	-80.18M	-3.5494
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-11-25	Resumed	H.C. Wainwright	Buy
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-13-24	Initiated	Cantor Fitzgerald	Overweight
Aug-13-24	Initiated	Jefferies	Buy
Aug-13-24	Initiated	Needham	Buy
Aug-13-24	Initiated	TD Cowen	Buy
Aug-13-24	Initiated	Wedbush	Outperform

View All

Artiva Biotherapeutics Inc Stock (ARTV) Latest News

Aug 11, 2026

What is HC Wainwright's Forecast for ARTV Q3 Earnings? - MarketBeat

Aug 11, 2026

Aug 10, 2026

Artiva Biotherapeutics (ARTV) Slips to $11.22 as Stock Holds Above Key SupportSmart Beta Flow - dars.gov.et

Aug 10, 2026

Aug 08, 2026

Wall Street Zen Upgrades Artiva Biotherapeutics (NASDAQ:ARTV) to Hold - MarketBeat

Aug 08, 2026

TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Announces Target Price $11.58 - Moomoo

Aug 08, 2026

Aug 07, 2026

H.C. Wainwright Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $35 - Moomoo

Aug 07, 2026

ARTIVA BIOTHERAPEUTICS INC: QTRLY EPS $-0.63 - webull.com

Aug 07, 2026

Artiva Therapeutics: Buy Rating Reiterated on Strong AlloNK RA Profile and Upcoming Phase III, Price Target Maintained at $41 - TipRanks

Aug 07, 2026

Artiva Therapeutics: Buy Rating Reiterated on Promising RA Data, Clear Phase 3 Path and Maintained $35 Price Target - TipRanks

Aug 07, 2026

Aug 06, 2026

Certain Restricted Stock Units of Artiva Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-AUG-2026. - marketscreener.com

Aug 06, 2026

Certain Stock Options of Artiva Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-AUG-2026. - marketscreener.com

Aug 06, 2026

Artiva Biotherapeutics (NASDAQ:ARTV) Announces Quarterly Earnings Results - MarketBeat

Aug 06, 2026

Artiva Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 06, 2026

Artiva Biotherapeutics reports Q2 2026 net loss $25.0M, cash $349.4M to fund operations into 2029 - TradingView

Aug 06, 2026

FDA RMAT designation for AlloNK plus rituximab boosts Artiva Biotherapeutics, Inc. clinical progress - tradersunion.com

Aug 06, 2026

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo! Finance Canada

Aug 06, 2026

Aug 03, 2026

Form DEF 14A Artiva Biotherapeutics For: 3 August By Investing.com - Investing.com Nigeria

Aug 03, 2026

Aug 01, 2026

Ra capital management, 10% owner, acquires $455,725 Artiva stock By Investing.com - Investing.com Australia

Aug 01, 2026

Form 4 Artiva Biotherapeutics Inc For: 1 August By Investing.com - Investing.com UK

Aug 01, 2026

Jul 31, 2026

RA Capital Management buys USD 456,297 of Artiva Biotherapeutics common shares - Bitget

Jul 31, 2026

Jul 30, 2026

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Jul 30, 2026

Jul 29, 2026

Form 4 Artiva Biotherapeutics Inc For: 28 July By Investing.com - Investing.com Nigeria

Jul 29, 2026

Jul 28, 2026

Ra capital management director buys $412,776 in Artiva Biotherapeutics By Investing.com - Investing.com Canada

Jul 28, 2026

Jul 27, 2026